See more : Edify Acquisition Corp. (EACPU) Income Statement Analysis – Financial Results
Complete financial analysis of Capricor Therapeutics, Inc. (CAPR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Capricor Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Galaxy Payroll Group Limited (GLXG) Income Statement Analysis – Financial Results
- NewPeak Metals Limited (NPMFF) Income Statement Analysis – Financial Results
- Minto Metals Corp. (MNTO.V) Income Statement Analysis – Financial Results
- USG Tech Solutions Limited (USGTECH.BO) Income Statement Analysis – Financial Results
- EssilorLuxottica Société anonyme (ESLOY) Income Statement Analysis – Financial Results
Capricor Therapeutics, Inc. (CAPR)
About Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.18M | 2.55M | 244.90K | 310.25K | 1.01M | 1.67M | 1.37M | 3.19M | 3.78M | 4.79M | 503.23K | 195.50K | 1.35M | 0.00 | 0.00 | 0.00 | 101.40K | 0.00 | 0.00 | 0.00 | 2.18K | 11.48K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.07M | 694.87K | 245.70K | 8.46M | 5.14M | 12.07M | 10.77M | 16.04M | 13.76M | 7.79M | 5.20M | 2.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 24.11M | 1.85M | -799.00 | -8.15M | -4.14M | -10.40M | -9.40M | -12.85M | -9.98M | -3.00M | -4.69M | -2.44M | 1.35M | 0.00 | 0.00 | 0.00 | 101.40K | 0.00 | 0.00 | 0.00 | 2.18K | 11.48K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 95.75% | 72.74% | -0.33% | -2,625.87% | -411.61% | -621.98% | -687.46% | -402.87% | -264.33% | -62.69% | -932.76% | -1,247.43% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 36.45M | 21.82M | 13.57M | 8.46M | 5.14M | 12.07M | 10.77M | 16.04M | 13.76M | 7.79M | 5.20M | 1.02M | 4.14M | 4.08M | 4.47M | 9.48M | 5.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 12.37M | 10.43M | 7.61M | 5.54M | 3.60M | 4.93M | 4.76M | 4.93M | 4.37M | 3.02M | 2.21M | 1.61M | 2.12M | 2.21M | 3.42M | 3.92M | 4.48M | 60.40K | 18.86K | 18.98K | 18.34K | 29.26K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.43K | 0.00 |
| SG&A | 12.37M | 10.43M | 7.61M | 5.54M | 3.60M | 4.93M | 4.76M | 4.93M | 4.37M | 3.02M | 2.21M | 1.61M | 2.12M | 2.21M | 3.42M | 3.92M | 4.48M | 60.40K | 18.86K | 18.98K | 18.34K | 29.26K | 22.22K | 10.43K | 0.00 |
| Other Expenses | 0.00 | 190.58K | 548.21K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 545.88K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 83.00 | 26.09K | 200.00 |
| Operating Expenses | 48.19M | 32.25M | 21.18M | 14.00M | 8.74M | 17.00M | 14.23M | 20.17M | 16.39M | 10.80M | 7.41M | 2.64M | 6.25M | 6.29M | 7.88M | 13.40M | 9.60M | 60.40K | 18.86K | 18.98K | 18.34K | 29.26K | 22.30K | 36.52K | 200.00 |
| Cost & Expenses | 49.26M | 32.25M | 21.18M | 14.00M | 8.74M | 17.00M | 14.23M | 20.17M | 16.39M | 10.80M | 7.41M | 2.64M | 6.25M | 6.29M | 7.88M | 13.40M | 9.60M | 60.40K | 18.86K | 18.98K | 18.34K | 29.26K | 22.30K | 36.52K | 200.00 |
| Interest Income | 1.73M | 0.00 | 57.46K | 32.94K | 94.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.23K | 6.01K | 20.38K | 47.19K | 332.72K | 287.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 398.81K | 344.67K | 248.63K | 200.51K | 58.13K | 0.00 | 0.00 | 0.00 | 0.00 | 137.00 | 1.09M | 950.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.07M | 694.87K | 245.70K | 143.89K | 171.96K | 157.65K | 144.17K | 134.64K | 110.87K | 41.90K | 26.92K | 6.26K | 7.51K | 12.93K | 159.59K | 113.29K | 26.98K | 0.00 | 0.00 | -900.00 | 0.00 | -2.19K | 83.00 | 200.00 | 200.00 |
| EBITDA | -23.01M | -29.16M | -20.69M | -13.55M | -7.56M | -15.17M | -12.72M | -18.33M | -12.50M | -5.97M | -6.88M | -1.89M | -4.88M | -6.02M | -7.71M | -13.02M | -9.50M | -2.50M | -18.86K | -19.88K | -16.16K | -19.97K | -22.22K | -36.32K | 200.00 |
| EBITDA Ratio | -91.39% | -1,184.21% | -8,700.01% | -4,423.18% | -778.68% | -917.04% | -940.79% | -532.16% | -334.00% | -124.85% | -1,366.36% | -1,244.33% | -361.76% | 0.00% | 0.00% | 0.00% | -9,342.68% | 0.00% | 0.00% | 0.00% | -739.79% | -173.90% | 0.00% | 0.00% | 0.00% |
| Operating Income | -24.08M | -29.70M | -20.94M | -13.69M | -7.73M | -15.33M | -12.86M | -16.98M | -12.61M | -6.02M | -6.90M | -2.44M | -4.90M | -6.29M | -7.88M | -13.40M | -9.50M | -60.40K | -18.86K | -18.98K | -16.16K | -17.78K | -22.30K | -36.52K | -200.00 |
| Operating Income Ratio | -95.63% | -1,165.10% | -8,549.86% | -4,412.56% | -769.52% | -917.04% | -940.79% | -532.16% | -334.00% | -125.72% | -1,371.71% | -1,248.15% | -361.70% | 0.00% | 0.00% | 0.00% | -9,369.29% | 0.00% | 0.00% | 0.00% | -739.79% | -154.82% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.79M | 677.85K | 915.92K | 32.94K | 92.07K | 135.99K | 15.29M | -1.83M | -245.51K | -198.61K | -1.99M | 207.00K | 14.39K | 262.06K | 11.41K | 268.39K | -802.34K | -950.00 | 0.00 | 900.00 | 16.16K | 2.19K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -22.29M | -29.02M | -20.02M | -13.66M | -7.64M | -15.19M | 2.43M | -18.81M | -12.86M | -6.22M | -8.89M | -1.89M | -4.88B | -6.03B | -7.87B | -13.13B | -10.30M | -61.35K | 0.00 | -18.08K | 0.00 | -15.59K | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -88.52% | -1,138.50% | -8,175.86% | -4,401.94% | -760.36% | -908.91% | 177.84% | -589.53% | -340.50% | -129.87% | -1,766.96% | -968.31% | -360,633.89% | 0.00% | 0.00% | 0.00% | -10,160.55% | 0.00% | 0.00% | 0.00% | 0.00% | -135.73% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -677.85 | -613.41K | -176.83K | -264.03K | 135.99K | 254.63K | 218.95K | 137.76K | 200.51K | 58.13K | 0.00 | -14.39K | -262.06K | -11.41K | -268.39K | 1.09M | 0.00 | 18.86K | 0.00 | 16.16K | 0.00 | 0.00 | 0.00 | 200.00 |
| Net Income | -22.29M | -29.02M | -19.41M | -13.48M | -7.38M | -15.19M | 2.43M | -18.81M | -12.86M | -6.22M | -8.89M | -1.89M | -4.88M | -6.03M | -7.87M | -13.13M | -10.30M | -61.35K | -18.86K | -18.08K | -16.16K | -15.59K | -22.30K | -36.52K | -200.00 |
| Net Income Ratio | -88.52% | -1,138.48% | -7,925.38% | -4,344.95% | -734.09% | -908.91% | 177.84% | -589.53% | -340.50% | -129.87% | -1,766.96% | -968.31% | -360.63% | 0.00% | 0.00% | 0.00% | -10,160.55% | 0.00% | 0.00% | 0.00% | -739.79% | -135.73% | 0.00% | 0.00% | 0.00% |
| EPS | -0.83 | -1.18 | -0.84 | -0.87 | -1.99 | -5.17 | 1.00 | -10.14 | -8.09 | -5.31 | -8.47 | -1.90 | -65.43 | -93.75 | -154.56 | -272.15 | -304.06 | -2.22 | -12.49 | -11.97 | -10.70 | -10.32 | -14.77 | -26.56 | -0.20 |
| EPS Diluted | -0.83 | -1.18 | -0.84 | -0.87 | -1.99 | -5.17 | 0.90 | -10.14 | -8.09 | -5.31 | -8.47 | -1.90 | -65.43 | -93.75 | -154.56 | -272.15 | -304.06 | -2.22 | -12.49 | -11.97 | -10.70 | -10.32 | -14.77 | -26.56 | -0.20 |
| Weighted Avg Shares Out | 26.78M | 24.55M | 23.09M | 15.57M | 3.71M | 2.94M | 2.32M | 1.86M | 1.59M | 1.17M | 1.05M | 994.52K | 74.66K | 64.34K | 50.93K | 48.25K | 33.88K | 27.59K | 1.51K | 1.51K | 1.51K | 1.51K | 1.51K | 1.38K | 1.00K |
| Weighted Avg Shares Out (Dil) | 26.78M | 24.55M | 23.09M | 15.57M | 3.71M | 2.94M | 2.68M | 1.86M | 1.59M | 1.17M | 1.05M | 994.53K | 74.66K | 64.34K | 50.93K | 48.25K | 33.88K | 27.59K | 1.51K | 1.51K | 1.51K | 1.51K | 1.51K | 1.38K | 1.00K |
Capricor (CAPR) Surges 18.2%: Is This an Indication of Further Gains?
Capricor (CAPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will host an investor webcast on Tuesday, September 24,...
Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
-Capricor to Receive $15 Million Equity Investment at a 20% Premium, as well as $20 Million Upfront Payment upon Signing Definitive Agreement with up to $715 Million in Potential Milestones and a Double-Digit Percentage of Product Revenue-
Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences
SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to present at various upcoming investor...
Capricor Therapeutics, Inc. (CAPR) Q2 2024 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Linda Marban – Chief Executive Officer AJ Bergmann – Chief Financial Officer Conference Call Participants Joseph Pantginis – H.C. Wainwright Leland Gershell...
Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue Estimates
Capricor Therapeutics (CAPR) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.29 per share a year ago.
CORRECTION: Capricor Therapeutics
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by Capricor Therapeutics, please note that the words "Pre-BLA Meeting with...
Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has scheduled a...
Capricor: Rolling BLA Submission Of CAP-1002 To Get DMD Treatment Program Going
Capricor Therapeutics, Inc.'s rolling BLA submission of CAP-1002 for the treatment of patients with DMD, expected in Q3 of 2024. Top-line results from Cohort A of the phase 3 HOPE-3 study, using CAP-1002 for the treatment of patients with DMD,...
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
--FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results-- SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for...
Source: https://incomestatements.info
Category: Stock Reports